
Overview
Dr. Pettit studied physics and magazine journalism at Syracuse University prior to earning her MD from the Chicago Medical School. She went on to complete her residency in internal medicine and fellowships in hematology/oncology and clinical pharmacology/pharmacogenomics at the University of Chicago. She has received national recognition for her research, including the Conquer Cancer Foundation/ASCO Young Investigator Award, the ASCPT Presidential Trainee Award, and selection for the ASH Clinical Research Training Institute. Dr. Pettit focuses on translational research and drug development for patients with myeloid malignancies, specifically myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.
Dr. Pettit is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Splenectomy.
Dr. Pettit is board certified in Hematology and Medical Oncology. She is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 5 clinical trials. Dr. Pettit is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- HMO
- OTHER MEDICAID
- STATE MEDICAID
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- POS
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1540 E Hospital Dr, Floor 7 Reception B, Ann Arbor, MI 48109
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
5 Clinical Trials
Rogel Cancer Center
Rashmi Chugh is an Oncologist and a Hematologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma. Dr. Chugh is currently accepting new patients.
Rogel Cancer Center
Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology. Dr. Worden is currently accepting new patients.
Rogel Cancer Center
Scott Schuetze is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma. Dr. Schuetze is currently accepting new patients.
C. S. Mott Children's Hospital
Dr. Dale Bixby has been practicing hematology at the University of Michigan since 2009. He obtained his PhD in Medicinal Chemistry and Pharmaceutics at the University of Kentucky in 1999, before beginning his medical training at the University of Michigan in Ann Arbor, MI. He was a resident in the Department of Internal Medicine and then completed fellowship training in hematology and medical oncology at the University of Michigan. Dr. Bixby is currently a clinical professor and specializes in the areas of myeloid and lymphoid leukemias, myelodysplastic syndrome and bone marrow failure disorders. Dr. Bixby currently serves as the section chief of the acute leukemia program. He is also a clinical investigator in hematological malignancies. Dr. Bixby is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is board certified in Hematology. Dr. Bixby is currently accepting new patients.
Rogel Cancer Center
Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology. Dr. Vaishampayan is currently accepting new patients.
Rogel Cancer Center
The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is highly rated in 24 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr. Wilcox is currently accepting new patients.
Frequently Asked Questions about Dr. Kristen M. Pettit
How do I make an appointment with Dr. Kristen M. Pettit?
You can book an appointment with Dr. Kristen M. Pettit by calling their office at 734-647-8902. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Kristen M. Pettit a top-rated expert for Myelofibrosis?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kristen M. Pettit is classified as an Elite expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Kristen M. Pettit specialize in?
While Dr. Kristen M. Pettit is a Hematology, they have specific expertise in Myelofibrosis, Acute Myeloid Leukemia (AML), and Myeloproliferative Neoplasms (MPN). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.
Does Dr. Kristen M. Pettit participate in research or clinical trials?
Yes. Dr. Kristen M. Pettit has published 61 articles and abstracts on conditions like Myelofibrosis. You can view a list of Dr. Kristen M. Pettit's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Kristen M. Pettit accept my insurance?
Dr. Kristen M. Pettit accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 734-647-8902 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- MyelofibrosisDr. Pettit isElite. Learn about Myelofibrosis.
- Distinguished
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Pettit isDistinguished. Learn about Acute Myeloid Leukemia (AML).
- Childhood Acute Myeloid LeukemiaDr. Pettit isDistinguished. Learn about Childhood Acute Myeloid Leukemia.
- Chronic Myelogenous Leukemia (CML)Dr. Pettit isDistinguished. Learn about Chronic Myelogenous Leukemia (CML).
- Chronic Myelomonocytic Leukemia (CMML)Dr. Pettit isDistinguished. Learn about Chronic Myelomonocytic Leukemia (CMML).
- Essential ThrombocythemiaDr. Pettit isDistinguished. Learn about Essential Thrombocythemia.
- Myelodysplastic Syndrome (MDS)Dr. Pettit isDistinguished. Learn about Myelodysplastic Syndrome (MDS).
- Myeloproliferative Neoplasms (MPN)Dr. Pettit isDistinguished. Learn about Myeloproliferative Neoplasms (MPN).
- Polycythemia VeraDr. Pettit isDistinguished. Learn about Polycythemia Vera.
- Systemic MastocytosisDr. Pettit isDistinguished. Learn about Systemic Mastocytosis.
- Advanced
- Acute Lymphoblastic Leukemia (ALL)
- Acute Monoblastic Leukemia (AmoL)Dr. Pettit isAdvanced. Learn about Acute Monoblastic Leukemia (AmoL).
- Acute Myeloblastic Leukemia with Maturation
- Acute Promyelocytic LeukemiaDr. Pettit isAdvanced. Learn about Acute Promyelocytic Leukemia.
- Aleukemic Leukemia Cutis (ALC)Dr. Pettit isAdvanced. Learn about Aleukemic Leukemia Cutis (ALC).
- AnemiaDr. Pettit isAdvanced. Learn about Anemia.
- Aplastic AnemiaDr. Pettit isAdvanced. Learn about Aplastic Anemia.
- Bone Marrow AspirationDr. Pettit isAdvanced. Learn about Bone Marrow Aspiration.
- Castleman DiseaseDr. Pettit isAdvanced. Learn about Castleman Disease.
- GangliogliomaDr. Pettit isAdvanced. Learn about Ganglioglioma.
- LeukemiaDr. Pettit isAdvanced. Learn about Leukemia.
- Multicentric Castleman Disease (MCD)
- Philadelphia-Negative Chronic Myeloid Leukemia
- POEMS SyndromeDr. Pettit isAdvanced. Learn about POEMS Syndrome.
- SplenomegalyDr. Pettit isAdvanced. Learn about Splenomegaly.
- ThrombocytopeniaDr. Pettit isAdvanced. Learn about Thrombocytopenia.
- Unicentric Castleman Disease (UCD)
- Experienced
- Acute Erythroid Leukemia (AEL)Dr. Pettit isExperienced. Learn about Acute Erythroid Leukemia (AEL).
- Adult T-Cell LeukemiaDr. Pettit isExperienced. Learn about Adult T-Cell Leukemia.
- AgranulocytosisDr. Pettit isExperienced. Learn about Agranulocytosis.
- Budd-Chiari SyndromeDr. Pettit isExperienced. Learn about Budd-Chiari Syndrome.
- Chronic B-Cell Leukemia (CBCL)Dr. Pettit isExperienced. Learn about Chronic B-Cell Leukemia (CBCL).
- Chronic Familial NeutropeniaDr. Pettit isExperienced. Learn about Chronic Familial Neutropenia.
- Chronic Lymphocytic Leukemia (CLL)Dr. Pettit isExperienced. Learn about Chronic Lymphocytic Leukemia (CLL).
- Chronic T-Cell Leukemia (CTCL)Dr. Pettit isExperienced. Learn about Chronic T-Cell Leukemia (CTCL).
- Diffuse Large B-Cell Lymphoma (DLBCL)Dr. Pettit isExperienced. Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
- Febrile NeutropeniaDr. Pettit isExperienced. Learn about Febrile Neutropenia.
- Hairy Cell Leukemia (HCL)Dr. Pettit isExperienced. Learn about Hairy Cell Leukemia (HCL).
- Large-Cell Immunoblastic LymphomaDr. Pettit isExperienced. Learn about Large-Cell Immunoblastic Lymphoma.
- LeukocytosisDr. Pettit isExperienced. Learn about Leukocytosis.
- Mast Cell Activation Syndrome (MCAS)Dr. Pettit isExperienced. Learn about Mast Cell Activation Syndrome (MCAS).
- Prolymphocytic LeukemiaDr. Pettit isExperienced. Learn about Prolymphocytic Leukemia.
- ReticuloendotheliosisDr. Pettit isExperienced. Learn about Reticuloendotheliosis.
- Richter SyndromeDr. Pettit isExperienced. Learn about Richter Syndrome.
- Sideroblastic AnemiaDr. Pettit isExperienced. Learn about Sideroblastic Anemia.
- SplenectomyDr. Pettit isExperienced. Learn about Splenectomy.
- T-Cell LymphomaDr. Pettit isExperienced. Learn about T-Cell Lymphoma.





